Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia.
Kvasnicka
Hans Michael
HM
Institute of Pathology, University of Cologne, Cologne, Germany. hm.kvasnicka@uni-koeln.de
Thiele
Juergen
J
Schmitt-Graeff
Annette
A
Diehl
Volker
V
Niederle
Norbert
N
Schaefer
Hans Eckart
HE
D001853:Bone Marrow / Q000473:pathology*; D015672:Erythroid Precursor Cells / Q000187:drug effects; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000494:pharmacology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D055728:Primary Myelofibrosis / Q000188:drug therapy; D011379:Prognosis; D011994:Recombinant Proteins; D018570:Risk Assessment; D016019:Survival Analysis
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D006918:Hydroxyurea